BGG World, a wholly-owned subsidiary of HB Natural Ingredients (HBNI), announced that it will be featuring its Vitosa Stevia at the upcoming Natural Products Expo West in Anaheim, CA.
Photo © iStockphoto.com/ olm26250
BGG World (Irvine, CA), a wholly-owned subsidiary of HB Natural Ingredients (HBNI), announced that it will be featuring its Vitosa Stevia at the upcoming Natural Products Expo West in Anaheim, CA. The sweetener is said to closely mimic sugar, and lacks the bitterness and aftertaste frequently associated with other stevia products. Available in three different taste profiles, Vitosa is water soluble, and has dual functionality, serving as a sweetness enhancer and as a standalone sweetener that is FDA and FEMA GRAS (generally recognized as safe).
“With the introduction of Vitosa, we have taken a product that was poorly viewed in the sweetener category due to a bitter aftertaste and made something extremely palatable, yet healthy for individuals seeking reduced sugar intake,” said Shaheen Majeed, CEO of BGG Americas and HBNI USA.
BGG will be exhibiting Vitosa and other ingredients at booth #4645.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.